Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life

Michael Steiner, Gunasekaran Ramakrishnan, Britta Gartner, Olivier Van Der Meeren, Jeanne-Marie Jacquet, Volker Schuster, Michael Steiner, Gunasekaran Ramakrishnan, Britta Gartner, Olivier Van Der Meeren, Jeanne-Marie Jacquet, Volker Schuster

Abstract

Background: Few studies have assessed long term persisting immunity against hepatitis B virus (HBV) in children vaccinated during infancy with combined vaccines containing recombinant HBV surface antigen (HBs). We assessed antibody persistence and immune memory in children 4-5 years of age, previously vaccinated with four doses of combined hexavalent DTPa-HBV-IPV/Hib vaccine (Infanrix hexa).

Methods: Immune memory was assessed in 301 children through administration of a challenge dose of monovalent HBV vaccine.

Results: At 4-5 years of age, 85.3% of subjects had persisting anti-HBs antibody concentrations >or= 10 mIU/mL, rising to 98.6% after the HBV challenge dose. All but 12 subjects (95.8%) achieved post-challenge anti-HBs concentrations >or= 100 mIU/mL. The post-challenge anti-HBs GMC rose by 100-fold compared to pre-challenge concentrations. An anamnestic response to the HBV vaccine challenge was observed in 96.8% of subjects, including 17/21 (81.0%) of children with initially undetectable antibodies (<3.3 mIU/mL). All but 4 of 42 subjects (90.5%) with anti-HBs antibodies <10 mIU/mL prior to the challenge dose, achieved seroprotective levels afterwards. A 4-fold rise in antibody concentration after the challenge dose was observed in 259/264 (98.1%) of initially seropositive subjects. The magnitude of the post-challenge responses was proportional to pre-challenge anti-HBs levels. No serious adverse events were reported during the study.

Conclusion: The combined DTPa-HBV-IPV/Hib vaccine induced lasting immune memory against hepatitis B. Long term protection afforded by DTPa-HBV-IPV/Hib is likely to be similar to that observed following priming with monovalent HBV vaccines.

Trial registration: http://www.clinicaltrials.gov 106789 NCT00411697.

Figures

Figure 1
Figure 1
Relationship between anti-HBs antibody concentrations before and after HBV challenge (ATP Immunogenicity cohort).

References

    1. World Health Organization. Hepatitis B vaccines WHO position paper. WER. 2004;79:255–263.
    1. World Health Organization. Progress in the control of viral hepatitis: memorandum from a WHO meeting. Bull WHO. 1988;66:443–455.
    1. Lawrence MH, Goldstein MA. Hepatitis B immunization in adolescents. J Adolesc Health. 1995;17:234–243. doi: 10.1016/1054-139X(95)00165-O.
    1. Centers for Disease Control and Prevention. Hepatitis B Virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP) MMWR. 1991;40(RR-13):1–19.
    1. Brabin L, Greenberg DP, Hessel L, Hyer R, Ivanoff B, Van Damme P. Current issues in adolescent immunization. Vaccine. 2008;26:4120–34. doi: 10.1016/j.vaccine.2008.04.055.
    1. Heininger U, Loos K, Lorenz I, Rascher W. Compliance with recommended immunizations in adolescents. Eur J Pediatr. 2006;165:671–676. doi: 10.1007/s00431-006-0161-9.
    1. Vandermeulen C, Roelants M, Theeten H, Depoorter AM, Van Damme P, Hoppenbrouwers K. Vaccination coverage in 14-year-old adolescents: documentation, timeliness, and sociodemographic determinants. Pediatrics. 2008;121:e428–434. doi: 10.1542/peds.2007-1415.
    1. Freed GL, Cowan AE, Clark SJ, Santoli J, Bradley J. Use of a new combined vaccine in pediatric practices. Pediatrics. 2006;118:e251–257. doi: 10.1542/peds.2006-0114.
    1. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25:507–512. doi: 10.1097/01.inf.0000222413.47344.23.
    1. Zepp F, Schmitt J, Cleerbout J, Verstraeten T, Schuerman L, Jacquet J-M. Review of eight years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine) Exp Rev Vaccines. 2009;8:663–679. doi: 10.1586/erv.09.32.
    1. Lim FS, Han HH, Jacquet JM, Bock HL. Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine. Ann Acad Med Singapore. 2007;36:801–806.
    1. Cambron P, Jacquet J-M, Hoet B, Lievens M. Development and Technical and Clinical Validation of a Quantitative Enzyme-Linked Immunosorbent Assay for the Detection of Human Antibodies to Hepatitis B Surface Antigen in Recipients of Recombinant Hepatitis B Virus Vaccine. Clin Vacc Immunol. 2009;16:1236–1246. doi: 10.1128/CVI.00431-08.
    1. Heininger U. DTP-HBV-IPV-059 Study Group; DTP-HBV-IPV-096 Study Group. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine. 2007;25:1055–1063. doi: 10.1016/j.vaccine.2006.09.060.
    1. Zinke M, Kappes R, Kindler K, Paulus-Koschik A, Goering U, Disselhoff J, Soemantri P, Grunert D, Laakmann H, Gunasekaran R, Gartner B, Jacquet J-M. Immune memory to hepatitis B virus in 4-to-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Human Vaccines. 2009;5:592–598.
    1. Giambi C, Bella A, Barale A, Montu D, Marchisio M, Oddone M, Zito S, Rapicetta M, Chionne P, Madonna E, degli Atti ML. A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. BMC Infect Dis. 2008;8:100. doi: 10.1186/1471-2334-8-100.
    1. World Health Organization. Document WHO/V&B/02.28, 2002. Geneva, WHO; 2002. Core information for the development of immunization policy.
    1. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet. 2000;355:561–565. doi: 10.1016/S0140-6736(99)07239-6.
    1. Alfaleh F, Alshehri S, Alansari S, Aljeffri M, Almazrou Y, Shaffi A, Abdo AA. Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infect. 2008;57:404–409. doi: 10.1016/j.jinf.2008.08.008.
    1. Sande MA van der, Waight PA, Mendy M, Zaman S, Kaye S, Sam O, Kahn A, Jeffries D, Akum AA, Hall AJ, Bah E, McConkey SJ, Hainaut P, Whittle HC. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS ONE. 2007;2:e753. doi: 10.1371/journal.pone.0000753.
    1. Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis. 2007;5:79–84. doi: 10.1016/j.tmaid.2006.04.004.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться